Update shared on05 Sep 2025
As both the Future P/E ratio and Net Profit Margin for IOL Chemicals and Pharmaceuticals remained effectively unchanged, the consensus analyst price target was maintained at ₹110.00.
What's in the News
- Board approved formation of a wholly owned UK subsidiary to enhance local presence and better serve UK/EU customers, supporting global business expansion.
- Project initiated to create Unit 9B by partially converting an existing facility, dedicated to Minoxidil and intermediates production with a 120 MTPA capacity, at a cost of INR 55.0 million fully funded via internal accruals; completion expected by December 2025.
- Remaining part of the original facility will continue as multiproduct Unit 9A.
- Board meeting scheduled to consider and approve unaudited financial results for the quarter ended June 30, 2025.
Valuation Changes
Summary of Valuation Changes for IOL Chemicals and Pharmaceuticals
- The Consensus Analyst Price Target remained effectively unchanged, at ₹110.00.
- The Future P/E for IOL Chemicals and Pharmaceuticals remained effectively unchanged, moving only marginally from 20.17x to 20.10x.
- The Net Profit Margin for IOL Chemicals and Pharmaceuticals remained effectively unchanged, at 7.66%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.